非臨床試験市場-世界の産業規模、シェア、動向、機会、および予測、2018～2028年、試験タイプ別、試験別、治療領域別、エンドユーザー別、地域別、競合

世界の非臨床試験市場の2022年の市場規模は98億6,000万米ドルで、2028年までのCAGRは6.22%で、予測期間中に力強い成長が予測されています。

世界の非臨床試験市場は、製薬・医療産業のダイナミックかつ不可欠な構成要素であり、新薬や医療機器の開発・承認において極めて重要な役割を果たしています。この市場には、潜在的な治療法や治療法がヒトを対象として試験される前に行われる幅広い活動が含まれます。非臨床試験は、しばしば前臨床試験と呼ばれ、実験的な医薬品や医療製品の安全性、有効性、毒性を評価するために、動物、試験管内システム、またはコンピューターシミュレーションを用いて実施される一連の厳格な試験や評価が含まれます。世界の非臨床試験市場成長の主な促進要因の一つは、無数の健康状態や疾病に対処するための革新的な医薬品や医療機器に対する需要が増え続けていることです。その結果、製薬企業やバイオテクノロジー企業、学術研究機関は、自社製品が規制基準を満たし、ヒトに使用しても安全であることを確認するために、非臨床試験に多額の投資を行っています。このため、専門の開発業務受託機関（CRO）への非臨床試験サービスのアウトソーシングが急増し、市場の拡大にさらに拍車をかけています。

インシリコ・モデリングや人工知能などの技術の進歩は、薬物の挙動や毒性をより正確に予測できるようにすることで非臨床試験に革命をもたらし、その結果、大規模な動物実験の必要性を減らしています。さらに、米国のFDAや欧州のEMAなど、世界中の規制機関が非臨床試験に関する厳格なガイドラインを導入しており、医薬品開発プロセスにおける市場の重要性が高まっています。

主な市場促進要因

革新的な医薬品・医療機器に対する需要の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の非臨床試験市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 試験タイプ別（薬力学（PD）試験、薬物動態（PK）試験、毒性試験）
  • 試験別（in silico試験、in vitro試験、in vivo試験）
  • 治療領域別（腫瘍学、心血管、神経学、免疫学、その他）
  • エンドユーザー別（製薬・バイオテクノロジー企業、CRO、学術・政府研究機関、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 試験タイプ別
  • 試験別
  • 治療領域別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋の非臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 試験タイプ別
  • 試験別
  • 治療領域別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の非臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 試験タイプ別
  • 試験別
  • 治療領域別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の非臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 試験タイプ別
  • 試験別
  • エンドユーザー別
  • 治療領域別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の非臨床試験市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 試験タイプ別
  • 試験別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの非臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 試験タイプ別
  • 試験別
  • 治療領域別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 製品上市
• 合併と買収

第12章 世界の非臨床試験市場のSWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Labcorp Drug Development
• Charles River Laboratories
• PPD（Pharmaceutical Product Development）
• ICON plc
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca plc
• CMIC HOLDINGS Co., LTD
• ProPharma
• MorphoSys AG

第15章 戦略的提言

当社について＆免責事項

Global Non-Clinical Trials Market has valued at USD 9.86 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 6.22%through 2028. The Global Non-Clinical Trials Market represents a dynamic and essential component of the pharmaceutical and healthcare industries, playing a pivotal role in the development and approval of new drugs and medical devices. This market encompasses a wide range of activities that occur before a potential treatment or therapy is tested on human subjects. Non-clinical trials, often referred to as preclinical trials, involve a series of rigorous tests and evaluations conducted on animals, in vitro systems, or computer simulations to assess the safety, efficacy, and toxicity of experimental drugs and medical products. One of the key drivers behind the growth of the global non-clinical trials market is the ever-increasing demand for innovative pharmaceuticals and medical devices to address a myriad of health conditions and diseases. As a result, pharmaceutical and biotechnology companies, as well as academic research institutions, are heavily invested in non-clinical trials to ensure that their products meet regulatory standards and are safe for human use. This has led to a surge in the outsourcing of non-clinical trial services to specialized contract research organizations (CROs), further fueling market expansion.

Advancements in technology, such as in silico modeling and artificial intelligence, have revolutionized non-clinical trials by enabling more accurate predictions of drug behavior and toxicity, thus reducing the need for extensive animal testing. Additionally, regulatory agencies across the globe, including the FDA in the United States and the EMA in Europe, have implemented stringent guidelines for non-clinical trials, which has intensified the market's importance in the drug development process.

Key Market Drivers

Rising Demand for Innovative Pharmaceuticals and Medical Devices

The rising demand for innovative pharmaceuticals and medical devices is a primary driver behind the robust growth of the Global Non-Clinical Trials Market. As the global population ages and the prevalence of chronic diseases continues to escalate, there is an ever-increasing need for cutting-edge therapies and medical solutions. This burgeoning demand has propelled pharmaceutical and biotechnology companies, as well as academic research institutions, into an intense race to develop new drugs and devices that can address a wide spectrum of health conditions. Non-clinical trials, also known as preclinical trials, are instrumental in meeting this demand by providing a crucial testing ground for these innovative products before they advance to human clinical trials. These trials involve comprehensive assessments of safety, efficacy, and toxicity, which are essential for regulatory approval and eventual market access. As a result, the pharmaceutical and healthcare industries are heavily invested in conducting robust non-clinical trials to ensure their products not only meet the highest safety standards but also offer tangible therapeutic benefits.

The pharmaceutical sector, in particular, has witnessed a surge in research and development activities aimed at producing novel drugs and biologics. From precision medicine and gene therapies to immunotherapies and targeted therapeutics, these cutting-edge innovations require rigorous testing and validation in the non-clinical phase. This has led to a substantial increase in the demand for non-clinical trial services and expertise. Moreover, the rapid advancement of medical devices, including wearables, diagnostic tools, and implantable technologies, has further fueled the need for robust non-clinical assessments. These devices are often designed to enhance patient care, improve diagnostics, or offer novel treatment modalities.

Outsourcing to Contract Research Organizations (CROs)

Outsourcing to Contract Research Organizations (CROs) has emerged as a significant driver of growth in the Global Non-Clinical Trials Market. The pharmaceutical and healthcare industries have undergone a profound transformation as they seek to streamline operations, reduce costs, and enhance efficiency. In this context, CROs have become invaluable partners, offering specialized expertise, state-of-the-art infrastructure, and a wealth of experience in conducting non-clinical trials. One of the primary factors driving the outsourcing trend is the need for efficiency and cost-effectiveness. Developing and maintaining in-house non-clinical trial capabilities can be prohibitively expensive and resource-intensive for pharmaceutical and biotechnology companies. CROs provide a cost-efficient alternative, enabling these organizations to focus on their core competencies-innovation and drug development-while leaving the complexities of non-clinical trial management to experts.

Moreover, CROs offer scalability and flexibility, allowing companies to adapt to fluctuating workloads and project demands. This flexibility is particularly crucial in the fast-paced and dynamic field of drug development, where timelines can be unpredictable. CROs can quickly allocate resources, assemble specialized teams, and initiate non-clinical trials, ensuring that projects stay on track and meet critical milestones. CROs also bring a global perspective to non-clinical trials. They often have a presence in multiple regions, providing access to diverse patient populations, regulatory environments, and scientific expertise. This global reach enhances the quality and diversity of data collected during non-clinical trials, which is essential for regulatory approval and market access in different countries.

Advancements in Technology

Advancements in technology have become a powerful catalyst for the remarkable growth of the Global Non-Clinical Trials Market. These innovations have revolutionized the way pharmaceutical and healthcare industries conduct preclinical or non-clinical trials, driving efficiency, accuracy, and cost-effectiveness to unprecedented levels. One of the most significant technological advancements is the integration of artificial intelligence (AI) and machine learning into non-clinical trial processes. AI algorithms can analyze vast datasets and identify patterns that might go unnoticed by human researchers. This capability is particularly valuable in predicting drug behavior, toxicity, and efficacy, reducing the reliance on extensive animal testing. AI-driven simulations and modeling allow researchers to make more precise predictions about how a drug or medical device will interact with the human body, significantly speeding up the development process.

In silico modeling, a form of computational simulation, has gained prominence in non-clinical trials. It enables scientists to create digital replicas of biological systems and simulate drug interactions with unprecedented accuracy. This approach not only saves time and resources but also contributes to reducing the need for animal testing. In silico modeling is particularly beneficial in identifying potential safety concerns and optimizing drug candidates before they advance to human trials. Additionally, advancements in laboratory automation and robotics have streamlined the non-clinical trial process. Automated systems can perform repetitive tasks with precision, increasing the speed and reproducibility of experiments. This reduces the risk of errors and ensures the consistency of results, which is critical for regulatory approval Furthermore, technologies like high-throughput screening and next-generation sequencing have enabled researchers to analyze a vast number of compounds, genes, and proteins simultaneously. This accelerates the drug discovery process by identifying promising candidates more efficiently and cost-effectively.

Key Market Challenges

Stringent Regulatory Compliance

Complex and Evolving Regulations: Regulatory agencies, such as the FDA in the United States and the EMA in Europe, have developed comprehensive guidelines that govern non-clinical trials. However, these regulations are intricate, subject to frequent updates, and can vary from one region to another. Navigating this complex regulatory landscape demands substantial expertise and resources, which can slow down the initiation and progression of non-clinical trials. Stringent Data and Documentation Requirements: Regulatory authorities require extensive documentation and data to support non-clinical trial submissions. Researchers must meticulously document every aspect of the trial, from study design and procedures to results and statistical analyses. This demanding documentation process can be time-consuming and resource-intensive, diverting valuable time and resources away from research activities.

Ethical and Patient Safety Considerations: Regulatory compliance often entails rigorous ethical considerations and a focus on patient safety. These ethical standards necessitate adherence to guidelines that protect the welfare of research subjects, whether they are animals or humans. Ensuring compliance with these ethical standards can lead to additional hurdles and delays, particularly when addressing the safety and well-being of trial participants. Meeting regulatory compliance requirements is resource-intensive. Companies and research organizations must invest in state-of-the-art facilities, skilled personnel, and advanced technologies to conduct non-clinical trials that satisfy regulatory standards.

Ethical Concerns and Animal Welfare

Non-clinical trials, an essential phase in drug development and medical research, have encountered a significant hurdle in recent years - ethical concerns and animal welfare issues. These challenges, driven by growing awareness and ethical considerations, have put pressure on the Global Non-Clinical Trials Market, influencing how trials are conducted and raising questions about the future of animal testing in biomedical research. One of the primary ethical concerns surrounding non-clinical trials is the use of animals as test subjects. Many preclinical studies involve the testing of potential pharmaceuticals and medical devices on animals, including rodents, dogs, primates, and more. This practice has been crucial in evaluating the safety and efficacy of new treatments before they progress to human trials. However, it has sparked intense debates and activism from animal rights groups, which argue that animals should not bear the burden of experimentation.

Public opinion and ethical considerations have pushed regulatory agencies to impose stricter guidelines on the use of animals in research. For example, the "3Rs" principle - Replacement, Reduction, and Refinement - encourages researchers to explore alternative testing methods, reduce the number of animals used, and refine procedures to minimize suffering. While these principles are important steps toward more ethical research practices, they also introduce complexities and costs that can hinder the efficiency of non-clinical trials.

Key Market Trends

Rise in Innovative Therapies

The Global Non-Clinical Trials Market is experiencing a substantial boost due to the relentless rise in demand for innovative therapies. As the global population grapples with an increasing burden of diseases, there has been an unmistakable call for transformative pharmaceuticals and medical devices to address these health challenges. This insatiable demand for groundbreaking treatments has spurred pharmaceutical and biotechnology companies, as well as academic research institutions, to intensify their research and development efforts. Consequently, non-clinical trials have taken center stage as a pivotal phase in the development of these innovative therapies.

In the current landscape, innovative therapies encompass a wide spectrum of cutting-edge approaches, including precision medicine, gene therapies, immunotherapies, and targeted therapeutics, among others. These novel treatments hold the promise of offering highly effective and personalized solutions for a range of health conditions, from rare genetic disorders to complex cancers. However, before these therapies can advance to human clinical trials and eventually reach patients, they must undergo rigorous assessment in non-clinical trials. Non-clinical trials serve as the essential bridge between laboratory research and clinical testing. They provide invaluable insights into the safety, efficacy, and toxicity of experimental drugs and medical devices. The demand for these trials has surged as pharmaceutical and biotechnology companies strive to meet regulatory standards, optimize therapeutic formulations, and ensure that their products deliver the intended benefits with minimal risks. Moreover, the ongoing trend of personalized medicine has further fueled the need for non-clinical trials. Tailoring treatments to individual patients based on their genetic makeup and specific health profiles requires a deep understanding of how therapies will interact with the human body.

Biotechnology Expansion

The Global Non-Clinical Trials Market is experiencing a remarkable surge, largely fueled by the expansion of the biotechnology sector. Biotechnology has emerged as a driving force behind groundbreaking medical innovations, with a strong focus on developing advanced therapies such as gene therapies, cell-based therapies, and biologics. These cutting-edge treatments hold tremendous promise in addressing complex diseases and unmet medical needs. However, their development necessitates rigorous testing, validation, and assessment of safety and efficacy, making non-clinical trials an integral component of the biotechnology landscape.

Biotechnology companies are at the forefront of developing innovative therapies that leverage the understanding of genetics, molecular biology, and cellular processes. These therapies often involve manipulating genetic material, engineering cells, or utilizing complex biological molecules. Consequently, non-clinical trials play a crucial role in comprehensively evaluating the safety profiles and effectiveness of these therapies before they advance to human clinical trials. Furthermore, the expansion of the biotechnology sector has led to a growing emphasis on personalized medicine. Tailoring treatments to individual patients based on their genetic makeup and specific health conditions requires precise understanding of how these therapies will interact with the human body. Non-clinical trials provide essential data on patient-specific responses, optimal dosages, and potential safety concerns, ensuring that personalized therapies are effective and safe.

Segmental Insights

Study Type Insights

Based on the study type, the Toxicology studies segment emerged as the dominant segment in the global market for Global Non-Clinical Trials Market in 2022. Toxicology studies are a fundamental component of non-clinical trials, and they are conducted to assess the safety of drugs and medical devices. These studies involve evaluating the potential toxicity of a substance by examining its effects on living organisms, typically using animal models.

Therapeutic Area Insights

Based on the therapeutic area, the oncology segment emerged as the dominant player in the global market for Global Non-Clinical Trials Market in 2022. Oncology, which focuses on the study and treatment of cancer, has been a major area of emphasis in pharmaceutical and biomedical research due to the significant global burden of cancer. Non-clinical trials in oncology involve the preclinical evaluation of potential cancer therapies, including novel drugs, immunotherapies, targeted therapies, and various treatment modalities such as chemotherapy and radiation therapy.

Regional Insights

North America emerged as the dominant player in the global Non-Clinical Trials Market in 2022, holding the largest market share.North America, particularly the United States, is home to a thriving pharmaceutical and biotechnology sector. The region boasts a large number of pharmaceutical companies, biotech startups, and research institutions that conduct extensive non-clinical trials. These organizations invest heavily in research and development, driving the demand for non-clinical trial services.

Key Market Players

Labcorp Drug Development

Charles River Laboratories

PPD (Pharmaceutical Product Development)

ICON plc

Novartis AG

Merck & Co., Inc.

AstraZeneca plc

Cmic Holdings Co., Ltd

ProPharma

MorphoSys AG

Report Scope:

In this report, the Global Non-Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Non-Clinical Trials Market, By Study Type:

• Pharmacodynamics (PD) studies
• Pharmacokinetics (PK) studies
• Toxicology studies

Global Non-Clinical Trials Market, By Test:

• In silico
• In vitro
• In vivo

Global Non-Clinical Trials Market, By Therapeutic Area:

• Oncology
• Cardiovascular
• Neurology
• Immunology
• Others

Global Non-Clinical Trials Market, By End User:

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic and Government Research Institutes
• Others

Global Non-Clinical Trials Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Non-Clinical Trials Market.

Available Customizations:

• Global Non-Clinical Trials Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Non-Clinical Trials Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Study Type (Pharmacodynamics (PD) studies, Pharmacokinetics (PK) studies, Toxicology studies)
  • 4.2.2. By Test (In silico, In vitro, In vivo )
  • 4.2.3. By Therapeutic Area (Oncology, Cardiovascular, Neurology, Immunology, Others)
  • 4.2.4. By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Government Research Institutes, Others )
  • 4.2.5. By Region
  • 4.2.6. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Study Type
  • 4.3.2. By Test
  • 4.3.3. By Therapeutic Area
  • 4.3.4. By End User
  • 4.3.5. By Region

5. Asia Pacific Non-Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Type
  • 5.2.2. By Test
  • 5.2.3. By Therapeutic Area
  • 5.2.4. By End User
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Non-Clinical Trials Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Study Type
      • 5.3.1.2.2. By Test
      • 5.3.1.2.3. By Therapeutic Area
      • 5.3.1.2.4. By End User
  • 5.3.2. India Non-Clinical Trials Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Study Type
      • 5.3.2.2.2. By Test
      • 5.3.2.2.3. By Therapeutic Area
      • 5.3.2.2.4. By End User
  • 5.3.3. Australia Non-Clinical Trials Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Study Type
      • 5.3.3.2.2. By Test
      • 5.3.3.2.3. By Therapeutic Area
      • 5.3.3.2.4. By End User
  • 5.3.4. Japan Non-Clinical Trials Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Study Type
      • 5.3.4.2.2. By Test
      • 5.3.4.2.3. By Therapeutic Area
      • 5.3.4.2.4. By End User
  • 5.3.5. South Korea Non-Clinical Trials Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Study Type
      • 5.3.5.2.2. By Test
      • 5.3.5.2.3. By Therapeutic Area
      • 5.3.5.2.4. By End User

6. Europe Non-Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Type
  • 6.2.2. By Test
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Non-Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Type
      • 6.3.1.2.2. By Test
      • 6.3.1.2.3. By Therapeutic Area
      • 6.3.1.2.4. By End User
  • 6.3.2. Germany Non-Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Type
      • 6.3.2.2.2. By Test
      • 6.3.2.2.3. By Therapeutic Area
      • 6.3.2.2.4. By End User
  • 6.3.3. Spain Non-Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Type
      • 6.3.3.2.2. By Test
      • 6.3.3.2.3. By Therapeutic Area
      • 6.3.3.2.4. By End User
  • 6.3.4. Italy Non-Clinical Trials Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Study Type
      • 6.3.4.2.2. By Test
      • 6.3.4.2.3. By Therapeutic Area
      • 6.3.4.2.4. By End User
  • 6.3.5. United Kingdom Non-Clinical Trials Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Study Type
      • 6.3.5.2.2. By Test
      • 6.3.5.2.3. By Therapeutic Area
      • 6.3.5.2.4. By End User

7. North America Non-Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test
  • 7.2.2. Study Type
  • 7.2.3. By End User
  • 7.2.4. By Therapeutic Area
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Non-Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Type
      • 7.3.1.2.2. By Test
      • 7.3.1.2.3. By Therapeutic Area
      • 7.3.1.2.4. By End User
  • 7.3.2. Mexico Non-Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Type
      • 7.3.2.2.2. By Test
      • 7.3.2.2.3. By Therapeutic Area
      • 7.3.2.2.4. By End User
  • 7.3.3. Canada Non-Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Type
      • 7.3.3.2.2. By Test
      • 7.3.3.2.3. By Therapeutic Area
      • 7.3.3.2.4. By End User

8. South America Non-Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Type
  • 8.2.2. By Test
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Non-Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Type
      • 8.3.1.2.2. By Test
      • 8.3.1.2.3. By Therapeutic Area
      • 8.3.1.2.4. By End User
  • 8.3.2. Argentina Non-Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Type
      • 8.3.2.2.2. By Test
      • 8.3.2.2.3. By Therapeutic Area
      • 8.3.2.2.4. By End User
  • 8.3.3. Colombia Non-Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Type
      • 8.3.3.2.2. By Test
      • 8.3.3.2.3. By Therapeutic Area
      • 8.3.3.2.4. By End User

9. Middle East and Africa Non-Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Non-Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Type
      • 9.3.1.2.2. By Test
      • 9.3.1.2.3. By Therapeutic Area
      • 9.3.1.2.4. By End User
  • 9.3.2. Saudi Arabia Non-Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Therapeutic Area
      • 9.3.2.2.4. By End User
  • 9.3.3. UAE Non-Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Type
      • 9.3.3.2.2. By Test
      • 9.3.3.2.3. By Therapeutic Area
      • 9.3.3.2.4. By End User
  • 9.3.4. Egypt Non-Clinical Trials Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Study Type
      • 9.3.4.2.2. By Test
      • 9.3.4.2.3. By Therapeutic Area
      • 9.3.4.2.4. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Non-Clinical Trials Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Labcorp Drug Development
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Charles River Laboratories
• 14.3. PPD (Pharmaceutical Product Development)
• 14.4. ICON plc
• 14.5. Novartis AG
• 14.6. Merck & Co., Inc.
• 14.7. AstraZeneca plc
• 14.8. CMIC HOLDINGS Co., LTD
• 14.9. ProPharma
• 14.10. MorphoSys AG

15. Strategic Recommendations

About Us & Disclaimer